Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.
B-Cell aplasia
BMI, body-mass index
COVID-19
COVID-19, Coronavirus Disease 2019
CRP, C-reactive protein
CT, computed tomography
ICU, intensive care unit
IL-2, interleukin 2
Immunodeficiency
Monoclonal antibodies
NK, natural killer
SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2
TNF-alpha, Tumor necrosis factor
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
07
2021
revised:
12
11
2021
accepted:
28
11
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
ppublish
Résumé
A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.
Identifiants
pubmed: 34868871
doi: 10.1016/j.rmcr.2021.101560
pii: S2213-0071(21)00222-7
pmc: PMC8628608
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101560Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Blood Adv. 2020 Nov 10;4(21):5373-5377
pubmed: 33137202
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Clin Infect Dis. 2020 Jul 28;71(15):748-755
pubmed: 32239127
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Ann Intern Med. 2020 Sep 15;173(6):499-501
pubmed: 32422085
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32404482
Neuroimmunomodulation. 2020;27(2):80-86
pubmed: 33341814
JAMA. 2021 Mar 2;325(9):880-881
pubmed: 33306087
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Br J Haematol. 2018 Jul;182(1):29-45
pubmed: 29741753
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet Rheumatol. 2020 Oct;2(10):e589-e590
pubmed: 33521659